Continuous whole blood glucose monitor

• US 20110009720A1
• Filed: 11/02/2007
• Published: 01/13/2011
• Est. Priority Date: 11/02/2006
• Status: Abandoned Application

• Current Assignee: Cascade Metrix, LLC
• Original Assignee: Cascade Metrix, Inc.
• Inventors: Kunjan, Kislaya, Lloyd, Frank Perry
• Application Number:
  US11/982,565
• Publication Number:
  US 20110009720A1
• Time in Patent Office: Days
• US Class Current: 600/316
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/15003 for venous or arterial blood
• CPC Class Codes: A61B 5/150221 Valves
• CPC Class Codes: A61B 5/150229 Pumps for assisting the blood sampling
• CPC Class Codes: A61B 5/150755 Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
• CPC Class Codes: A61B 5/150862 intermediate range, e.g. within room or building
• CPC Class Codes: A61B 5/150992 Blood sampling from a fluid line external to a patient, such as a catheter line, combined with an infusion line; blood sampling from indwelling needle sets, e.g. sealable ports, luer couplings, valves tubing connectors and couplings A61M39/00
• CPC Class Codes: A61B 5/155 Devices specially adapted for continuous or multiple sampling, e.g. at predetermined intervals devices loaded with multiple lancets simultaneously A61B5/15146
• CPC Class Codes: A61B 5/157 Devices characterised by integrated means for measuring characteristics of blood
• CPC Class Codes: A61M 1/34 Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
• CPC Class Codes: A61M 1/3406 Physical characteristics of the filtrate, e.g. urea
• CPC Class Codes: A61M 1/3496 Plasmapheresis; Leucopheresis; Lymphopheresis A61M1/3472 takes precedence
• CPC Class Codes: A61M 1/38 Removing constituents from donor blood and storing or returning remainder to body , e.g. for transfusion
• CPC Class Codes: A61M 2205/3306 Optical measuring means
• CPC Class Codes: A61M 2205/3313 used specific wavelengths
• CPC Class Codes: A61M 2205/7554 with means for unclogging or regenerating filters
• CPC Class Codes: A61M 2230/201 Glucose concentration

Abstract

A portable continuous whole blood glucose monitor comprising, a mid-infrared quantum cascade laser and driver in optical communication with a transmission cell and a photo-conductive detector and pre-amplifier. The monitor further comprises a peristaltic pump connected to a single lumen catheter peripherally inserted into a patient'"'"'s vein. The single lumen catheter, in combination with the peristaltic pump, is operable to automatically withdraw a fixed and metered amount of whole blood from a patient, then a tube delivers a fixed and metered amount of the saline/surfactant supply to the whole blood. Methods of enhancing measurement sensitivity are also provided.

Claims

1. A system for measuring an analyte in a complex matrix, comprising:

a mid-infrared quantum cascade laser emitting at least one wavelength;

a photo-detector;

a means for exposing a sample of the complex matrix to the laser and photo detector; and

a means for enhancing measurement sensitivity.

2. The system in claim 1, wherein the analyte is glucose.

3. The system in claim 2, wherein the matrix is selected from the group consisting of whole blood, plasma, serum, and ultrafiltrate.

4. The system in claim 1, wherein the system further comprises a thermo-electric cooler;

the laser and the photo-detector operate at room temperature being cooled by the thermoelectric cooler.

5. The system in claim 4, wherein:

the quantum cascade laser contains an external trigger that emits many mid-infrared electromagnetic radiation shots; and

the means for enhancing measurement comprises electronics;

including a time gate that coincides with the trigger;

a gated integrator designed to recover fast, repetitive, analog signals;

a boxcar averager with an active baseline subtraction module;

the photo detector converts the many radiation signals to analog signals and feeds the analog signals to the gated integrator that amplifies and integrates the analog signals present when the gate is open and ignores noise and interference during other times;

the boxcar averager averages the output of the gated integrator, and the active baseline subtraction module cancels baseline drift.

6. The system in claim 5, wherein the means for exposing the sample to the photo detector, comprises a fluidic system comprising, a transmission cell, a peristaltic pump, and a catheter, and a saline supply for rinsing the transmission cell.

7. The system in claim 6, wherein the transmission cell has a pair of mid-infrared transmissive windows spaced apart in the path of the mid-infrared electromagnetic radiation shots and the photo detector;

the peristaltic pump delivers the sample from the catheter to the transmission cell;

the spacing between the windows defines the optimal path length that enhances measurement sensitivity.

8. The system in claim 7, wherein the transmissive windows are preferably Zinc Selenide, but not excluding Zinc Sulfide, Silicon, and Polypropylene.

9. The system in claim 8, wherein one end of the catheter is inserted in a peripheral vein of a patient, whereas the other catheter end is connected to the peristaltic pump.

10. The system in claim 9, wherein the analyte is glucose, and the catheter dimensions are also sized to minimize blood consumption and lag time between whole blood withdrawal and glucose measurements.

11. The system in claim 10, wherein a method for preventing clogging and non-homogeneity of the matrix sample, and for preventing air bubbles in the transmission cell, comprises the step of using known methods in the industry.

12. The system in claim 10, wherein the fluidic system contains a non-ionic surfactant and saline supply, a catheter, a tube, and a mixing valve;

the catheter is inserted into a patient, for extracting a fixed and metered sample of the matrix, and is connected to the mixing valve;

the tube connects a fixed and metered amount of the surfactant and saline supply to the mixing valve;

both the sample and the matrix and the saline and surfactant are metered so that a dilution factor is controlled;

the peristaltic pump is connected to the mixing valve and the transmission cell;

the fluidic system draws metered samples of the matrix and the saline and surfactant;

then the fluidic system mixes the sample with the surfactant and saline;

then the peristaltic pump carries the mixture to the transmission cell;

then after the optical measurement, the transmission cell is rinsed with the surfactant and saline to prevent clogging and non-homogeneity on the surfaces of the transmissive windows during pumping the mixed sample through the transmission cell;

the non-ionic surfactant keeps a constant film in the transmission cell, by reducing surface tension, by lysing red blood cells and other cells that can cause optical instabilities in the measurement reading, by solubilizing proteins, and by homogenizing the matrix sample.

13. the system in claim 12, wherein the surfactant has a concentration range of about 0.1%-10%.

14. The system in claim 13, wherein the non-ionic surfactant is selected from the group consisting of Triton X-100 and Saponin.

15. The system in claim 14, wherein a heparin coating coats the inside surfaces of the fluidic system in contact with the sample matrix;

the heparin coating prevents clot formation along the flow path.

16. The system in claim 15, wherein the heparin coating may be of a covalent linkage type selected from the group consisting of the CBAS coating offered by Carmeda, and other complexes such as the TDMAC-Heparin Complex, and Heparin Benzalkonium Chloride Complex.

17. The system in claim 16, wherein in the catheter is a single lumen peripheral intravenous blood access catheter.

18. The system of claim 17, including signal processing hardware which converts the mid-infrared laser beam into electronic signals, and enhances the signal to noise ratio.

19. The system of claim 18, including a data acquisition card which converts the electronic signals into computer readable data;

and a glucose prediction application which reads the data, calculates the glucose concentration in the whole blood sample and displays the results on a computer.

20. The system of claim 19, wherein the infrared transmissive windows are a pair of circular windows made of a material selected from the group consisting of Zinc Selenide or Polypropylene with small optical apertures;

the spaced apart windows from a path length from microfluidic interface of a matrix sample and the transmission cell;

the path length is sized to allow the mid-infrared electromagnetic radiation signal to pass through the matrix sample at an optimal intensity enhancing measurement sensitivity.

21. The system in claim 20, wherein the laser is a tunable, multi-wavelength, mid-infrared quantum cascade laser.

23. A method for monitoring an analyte in a complex matrix, comprising:

the step of connecting a catheter to a peripheral vein of a patient and a fluid mixing valve;

the step of connecting a tube to a non-ionic surfactant and saline supply and the mixing valve;

the step of connecting the mixing valve to the peristaltic pump;

the step of connecting the peristaltic pump to a transmission cell having a path length sized to resolve the physiological concentrations of the analyte within the sample;

the step of integrating a processor with the peristaltic pump and mixing valve to draw fixed and metered amounts of both the matrix sample and of the non-ionic surfactant and saline;

the step of positioning the transmission cell in the optical electromagnetic radiation path of a mid-infrared quantum cascade laser and a photo-detector integrated with hardware and an algorithm configured to calculate the analyte concentration, and displaying the results on a computer;

the step of calibrating the laser and photo-detector to specify the laser intensity and the optimal set of wavelengths in a spectral region for the complex matrix where many wavelength terms may be required;

the step of activating the fluidic system to first draw metered samples of the matrix and the saline and surfactant;

then to mix the sample with the surfactant and saline;

then to carry the mixture to the transmission cell;

then after the optical measurement, rinse the transmission cell with the surfactant and saline to prevent clogging and non-homogeneity on the surfaces of the infrared transmissive windows during pumping the mixed sample through the transmission cell;

the non-ionic surfactant helping to keep a constant film in the transmission cell, by reducing surface tension, by lysing red blood cells and other cells that can cause optical instabilities in the measurement reading, by solubilizing proteins, and by homogenizing the matrix sample; and

the step of activating the laser trigger to shoot many shots through the transmission cell while the sample matrix passes.

22. The monitor of claim 23, wherein the tunable quantum cascade laser is centered at 9.4 μ

m having a ±

5 percent tunability around the center wavelength.

24. The method in claim 23, wherein the analyte is glucose and the complex matrix is selected from the group consisting of whole blood, plasma, and ultrafiltrate.

25. A method of blood sampling, comprising:

the step of inserting a single lumen catheter into a patient'"'"'s peripheral vein;

the step of withdrawing blood continuously or on demand by a peristaltic pump operating at a low speed to prevent any vein collapse and coating the fluidic path with heparin to prevent blood clotting.

26. A plasma extraction method, comprising:

the step of employing a porous membrane to harvest roughly half of the serum-plasma from the patient blood sample in a flow by operation where the filter membrane comprises the walls of a flow channel continuously extracting serum/plasma while the blood flows on its way to the waste container;

the step of interrogating the plasma sample;

the step of controlling the membrane geometry and the differential pressure across the membrane to harvest sufficient plasma for measurement while leaving enough to avoid plugging of the membrane;

the step of back flushing applying a controlled back flush of the plasma to avoid plugging of the membrane by blood cells; and

the step of regulating the flow rate of plasma sufficient to minimize lag time between blood withdrawal and glucose measurement.

27. An ultrafiltration extraction method, comprising:

the steps selected from the group consisting of the step of using ultrafiltration fibers to obtain ultrafiltration from the subcutaneous space of a patient or, the step of obtaining ultrafiltrate samples derived directly from vascular system by using hemofiltration.

29. The monitor in claim 27, wherein the monitor is portable, the microfluidic cartridge is separate from the optical subsystem, the microfluidic cartridge is disposable and insertable into the optical subsystem.

31. The monitor in claim 29, wherein the monitor is rechargeable and battery operated.

33. The monitor in claim 31, including a wireless transmitter capable of sending data, in a open or closed loop, to ancillary systems to help maintain tight glycemic control.

35. A method for determining optimal wavelengths of the multi-wavelength laser in claim 33, comprising:

the step of reducing each spectrum to a sum of pseudo spectra loading vectors;

the step of representing each spectrum by a unique set of scores, the set of coefficients required to reconstruct the original spectrum from the set of loading vectors using equation;

A=TB+E_A;

wherein A is the m×

n matrix of the calibration spectra;

wherein m spectra in the calibration set, each having n absorbance values;

wherein the spectra are reconstructed as a product of B (h×

n), the new basis set of loading vectors, and T (m×

h), the scores; and

,

the step of using the equation;

c=Tv+e_c to relate the unique set of scores to c the column matrix of concentrations.

28. A modular continuous whole blood glucose monitor, comprising:

a mid-infrared optical subsystem, including a tunable multi-wavelength mid-infrared quantum cascade laser, photo detector, electronics, and software; and

a microfluidic cartridge, including a transmission cell, a fluid selector valve, and blood access catheters.

30. The monitor in claim 28, wherein tile microfluidic cartridge displays glucose values both graphically and numerically.

32. The monitor in claim 30, including an alarm that activates whenever the glucose levels fall out of the safe range.

34. The monitor in claim 32, wherein life cycle of the microfluidic cartridge and the catheters set is at least 3 days, the typical time period a patient remains in ICU.

36. The monitor in claim 34, wherein the microfluidic cartridge is a fluidic system further comprising, mixing valve, a saline and non-ionic surfactant supply, and a heparin coating;

the transmission-cell including a pair of circular windows made of material selected from the group consisting of Zinc Selenide or Polypropylene with small optical apertures, spaced apart foiling a pathlength for microfluidic interface of a whole blood sample and the transmission cell;

the path length being sized to allow the mid-infrared laser electromagnetic signal to pass through the whole blood sample at an optimal intensity;

the catheter is sized to minimize blood consumption and lag time between whole blood withdrawal and glucose measurements;

all the inside surfaces of the fluidic system are coated with the heparin;

the catheter is inserted into a patient, for extracting a fixed and metered sample of the matrix, and is connected to the mixing valve;

the tube connects a fixed and metered amount of the surfactant and saline supply and mixing valve;

both the sample and the matrix and the saline and surfactant are metered so that a dilution factor is controlled;

the peristaltic pump is connected to the mixing valve and the transmission cell.

39. The monitor of claim 34, including a Mercury Cadmium Telluride detector package, comprising;

a response time of less than 9 nanosec, a detectivity of 7E9 cmHz^1/2/W, and a field of view of 38°

;

a detector chip and a preamplifier integrated together;

the Mercury Cadmium Telluride detector package provides shielding of the thermo-electric controller module;

the signal processing hardware comprising, a gated integrator module with a gate having a gate width;

a boxcar averager; and

a unique active baseline subtraction module;

the gated integrator and boxcar averager being designed to recover fast, repetitive, analog signals;

the gate width being sized and perfectly aligned with the external trigger on the quantum cascade laser driver, such that when the gate opens, the mid-infrared laser signal passes through the transmission cell and the gate, and is sensed by the Mercury Cadmium Telluride detector package, which feeds the mid-infrared laser signal into the gated integrator, which amplifies and integrates the mid-infrared laser signal while ignoring noise and interference that are present when the gate is closed;

the gated integrator then feeds the amplified and integrated mid-infrared signal into the Boxcar Averager, which averages the amplified and integrated mid-infrared signal improving the signal-to-noise ratio by a factor of the square root of the number of shots sampled; and

the active baseline subtraction module cancels baseline drift.

37. A continuous whole blood glucose monitor, comprising:

a sensor fluidic interface with a patient, a transmission cell, a single lumen catheter, a tube, a surfactant-saline supply, a mixer and a pump;

the sensor fluidic interface comprising;

a laser, a detector, a fiber coupled transmission probe comprising fiber bundles;

one end of the fiber bundles is connected to the detector and laser, the other end of the fiber bundles is proximal to a mirror to reflect the light from the laser back to the detector;

a transmission cell is fixed between the mirror and fiber-coupled transmission probe, a distance defining the path length of the transmission cell;

one end of the catheter is inserted into a patient'"'"'s peripheral vein, the one end of the tube is connected to the surfactant-saline supply, the other ends of the tube and catheter are connected to the mixer and pump;

the pump carries fixed and metered amounts of the blood sample mixed with fixed and metered amounts of the surfactant-saline supply through the transmission cell.

38. A continuous whole blood glucose monitor, comprising:

a fiber coupled transmission fluidic inter face with a patient;

the interface comprising a mid-infrared quantum cascade laser, a detector, a first fiber coupled transmission probe and a second fiber coupled transmission probe, each transmission probe comprising first and second ends, and containing fiber bundles or wave guides extending from the first end of each transmission probe to the second end of the transmission probe respectively;

two transparent windows spaced apart forming a path length;

one window connected to the first transmission probe second end, the other window connected to the second transmission probe first end;

a transmission cell in between the two windows;

a tube manifold for mixing a blood sample, an anti-coagulant, and a surfactant;

the first end of first transmission probe is proximal to the laser, the second end of the second transmission probe is connected to the detector;

a double lumen catheter, and a anti-coagulant surfactant supply;

one end of the catheter is inserted into a patient'"'"'s peripheral vein, the one end of the tube is connected to the surfactant-saline supply, the other ends of the tube and catheter are connected to the mixer and pump;

the pump carries fixed and metered amounts of the blood sample mixed with fixed and metered amounts of the surfactant-saline supply through the transmission cell, the light transmits from the laser through the first transmission probe through the flow cell, through the second transmission probe to the detector.

40. A bodily fluid monitor, comprising:

a Mid-infrared quantum cascade laser and a photo detector, each having collimating lenses;

an ATR ZnSe crystal prism having a tip the size of a pinhead; and

a silver halide Mid-infrared fiber connecting the laser and detector with the ATR prism;

which ATR prism remotely interfaces with a patient'"'"'s bodily fluid for glucose determination;

the laser Mid-infrared, electromagnetic signals bounce off the tip through the fiber, reflecting back to the detector;

the measurement sensitivity is determined by the tip design.

41. The monitor in claim 40, wherein the ATR prism tip has a hemispherical geometry, which design increases the path length by increasing the number of optical bounces.

42. The monitor in claim 41, wherein the detector is cryogenically cooled made of MCT, whose cooling increases detectivity.

43. A continuous whole blood glucose monitor, comprising:

a monochromatic, pulsed, multimode quantum cascade laser operating at around room temperature;

the quantum cascade laser comprising, a driver with an external trigger, the driver capable of generating a mid-infrared laser signal having a wavelength of 9.65 μ

m, a pulse frequency of 10 kHz, a pulse width of 100 ns, a peak power of 1000 mW;

a room temperature MCT detector package;

a thermo-electric controller module for maintaining the monitor around room temperature;

a fluidic system comprising a peristaltic pump, a demountable transmission based flow-cell, and a single lumen peripheral intravenous blood access catheter for transmitting a whole blood sample from a patient'"'"'s peripheral vein to the flow-cell, a tube;

signal processing hardware which converts the mid-infrared laser signals into analog signals;

a data acquisition card which converts the analog signals into digital signals; and

a glucose prediction algorithm which reads the data, calculates the glucose concentration in the whole blood sample and displays the results on a computer;

the quantum cascade laser and driver being in optical communication with the fluidic system and infrared integrated detector package;

the fluidic system further comprising, a fluid selector valve, a saline and surfactant supply, and a CBAS heparin coating having thickness of 0.2 μ

m and being non leaching, sterilizable, and hydrophilic;

the flow-cell including a pair of circular ZnSe windows spaced apart approximately 100 microns, forming a path length for microfluidic interface of a whole blood sample and the flow cell;

the path length being sized to allow the mid-infrared laser signal to pass through the whole blood sample at an optimal intensity;

the flow cell having a contained volume of less than 10 μ

l;

the catheter comprising, a sterilized capillary tubing with an outside diameter of 360 μ

m, an inside diameter of 150 μ

m, an inside surface, a first catheter end and a second catheter end, and a 22 gauge sheath;

the catheter dimensions minimize blood consumption and the lag time between whole blood withdrawal and glucose measurements;

all the inside surfaces of the fluidic system are coated with the heparin coating to prevent platelet adhesion and thrombus formation on the inside surfaces, while not diluting the whole blood sample, while reducing risk of trauma to the vascular system of the patient, and while avoiding heparin induced disorders to the patient;

the catheter is inserted into a patient, for extracting a fixed and metered sample of the whole blood, and is connected to the fluid selector valve;

the tube connects a fixed and metered amount of the surfactant and saline supply and mixing valve;

both the sample and the whole blood sample and the saline and surfactant are metered so that a dilution factor is controlled;

the peristaltic pump is connected to the fluid selector valve and the flow cell;

the fluid selector valve alternates between the saline and surfactant supply and the whole blood sample, every 5 minutes or at other user defined measurement intervals;

the MCT detector package, comprising;

a response time of less than 9 nsec, a detectivity of 7E9 cmHz^1/2/W, and a field of view of 38°

;

a detector chip and a preamplifier integrated together;

the MCT detector package provides shielding of the thermo-electric controller module;

the signal processing hardware comprising, a gated integrator module with a gate having a gate width;

a boxcar averager; and

a unique Active Baseline Subtraction module;

the gated integrator and boxcar averager being designed to recover fast, repetitive, analog signals;

the gate width being sized and perfectly aligned with the external trigger on the quantum cascade laser driver, the mid-infrared laser beam passes through the flow cell, and is sensed by the MCT detector package, which package feeds the transmitted signal into the gated integrator, which gated integrator amplifies and integrates the mid-infrared laser signal while ignoring noise and interference that are present when the gate is closed;

the gated integrator then feeds the amplified and integrated mid-infrared signal into the Boxcar Averager, which averager averages the amplified and integrated mid-infrared signal improving the signal-to-noise ratio by a factor of the square root of the number of shots; and

the Active Baseline Subtraction module cancels baseline drift.